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Table 1 Analyzed CD44, primer sequences and restriction enzyme.
Genes Location of polymorphisms Enzyme Forward-primer Reverse-primer
CD44 (rs7116432) Exon 19
þ779A>G
NlaIII CATCGTCTTCTTGCTGTTAGGA GGTCTTGGTTCAGGTAGGGAGA
CD44 (rs187116) Intron 1
þ4883G>A
MspI AGGTGGTTGGAGATCACCTG CTTTCGCAAGAACCACTTCC
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Introduction: Approximately more than 930,000 cases were
diagnosed with gastric cancer throughout the world. Overall Sur-
vival (OS) in patients with gastric cancer is less than 14 months.
In Iran, North and North West regions are at high risk of gastric
cancer. Significant differences in the frequency of environmental
risk factors give the country an opportunity to investigate the
causes of stomach cance. CD44 is the main molecule for cellular
connections and it plays an important role in a number of physio-
logical processes including cell attachment, migration and growth
regulation. In humans, the CD44 antigen is encoded by the CD44
gene on Chromosome 11. Moreover, CD44 increases proliferating
tumor cells in cooperation with membrane-bound receptor tyrosine
kinases containing C-src and C-erbB-2 (HER2/neu). Another
important function of CD44 is to regulate tumor cell binding and
motility. CD44 is involved in cell growth and metastasis formation
of gastric and colorectal cancer. According to the study in Califor-
nia of single nucleotide polymorphisms rs187116 and rs7116432
with TTR and OS, we investigated the presence of these polymor-
phisms among patients with gastric cancer in Iran. We also inves-
tigated whether there is a strong significant association between
these polymorphisms and clinical and pathological features of
patients.
Material & method: 150 patients with gastric cancer and 150
healthy subjects participated in the study. All patients in Imam
Reza and Omid Hospitals of Mashhad University of Medical Scien-
ces, from 1998 to 2010, were treated through surgery only or surgery
with (radio) chemotherapy. The study was approved by the Ethical
Committee of Mashhad University of Medical Sciences (MUMS)
and consent forms from all patients were obtained before any proce-
dures. Patients’ formalin-fixed paraffin-embedded (FFPE) tissues and
healthy people’s blood samples were taken. Then genomic DNA was
extracted using an extraction kit (QIAamp) according to the manufac-
turer's protocol. Samples were tested by restriction fragment length
polymorphism (PCR-RFLP) analysis or direct sequencing. Genes,
SNP reference identification numbers, location SNP, SNP perform-
ance, forward primer, reverse primer and restriction enzymes are
summarized in Table 1.
Joint and functional polymorphisms were selected in the CD44
gene according to previous articles. Our criteria for selecting a candi-
date gene polymorphism are as follows: low frequency of alleles 10%
 (MAF) in Caucasians and significant relationship with tumor
reccurence and overall survival (Table 1). The primary endpoints of
the analysis of polymorphisms in CD44 gene, included the time to
tumor recurrence (TTR) and overall survival (OS), calculated from
the date of diagnosis to date of the first observation of tumor recur-
rence or last follow-up, and the last case was used when the patient
did not undergo tumor recurrence at that time. The TTR was calcu-
lated from the date of diagnosis of the disease to the date of first
observation of tumor recurrence or until last follow-up if the patient
was recurrence-free at that time. The OS wad defined as the time
between disease diagnosis and death time to any cause or if thepatient was alive until the last call. Distribution of polymorphism
in connection with the main clinical and pathological demographic
characteristics using the chi-square test was investigated. OS and
TTR curves were analyzed based on COX regression. All statistical
tests are two-way and done using the SPSS Version 18. Mann-Whit-
ney test, which is a non-parametric test, was used to measure the age
difference between patients and healthy subjects. The Kruskal-Wallis
test, which compares three or more independent groups, was used for
age differences and different states of single nucleotide polymor-
phisms. Finally, to determine the factors that affect the survival,
Log Rank test were used.
Result: This research confirms the results by Winder et al in Cal-
ifornia that showed a strong significant association between rs187116
and rs711643 with TTR and OS in Iranian population. The presence
of at least one allele G for Polymorphism rs187116 was significantly
associated to decreased TTR and OS (P<0.0001). The presence of at
least one allele A for Polymorphism rs7116432 was significantly
associated to decreased TTR and OS (P<0.0001). We can use these
results for prognosis and early detection of patients at high risk for
tumor recurrence as an independent variable. Patients with diffuse
type has a two-fold increase in recurrence rate compared to patients
with intestinal yype (P<0.0001). However, type of tumor has no
effect on OS.
Discussion: CD44 is a very complexmoleculewith different roles
in cancer proliferation, invasion and metastasis. Recently collected
evidence suggests that this molecule is a gastric cancer stem cell
marker. It has been proven that overexpression ofCD44 variant exons
V8, V9 and V10 is associated with prognosis of gastric cancer. Pre-
vious studies have shown that CD44 gene polymorphisms can affect
the survival of cancers. The results of this study demonstrate that
there is a significant relationship between single nucleotide polymor-
phisms rs7116432 and rs187116 and gastric cancer. These results
show that the patients’ clinical outcomes can be predicted with
CD44 gene polymorphisms. The new findings prove that intron
changes may impact on the splicing regulatory elements that cause
the aberrant splicing. Patients with G/G genotype of CD44
rs187116 had shorter OS than patients with genotype A/A. The find-
ings may help select patients who are at high risk for recurrence so
that thay can benefit from specific therapeutic strategies.
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Introduction: Cancer is a leading cause of death worldwide.
Due to recent improvements in early detection and treatment, the
mortality rate has decreased in recent years, but treatment of
many cases remains quite sophisticated. Colorectal cancer is the
third major cause of cancer deaths in the United States both in
men and women. Novel therapeutic strategies are under investiga-
tion including using nanoparticles. In this brief review different
aspects of using nanoparticles in colorectal cancer stem cell are
discussed.
Cancer stem cell: Cancer stem cells (CSCs) are small subpopu-
lations of tumor cells responsible for the spread of cancer and
tumor growth in a very efficient manner. Perhaps one of the most
important causes of relapse and resistance to treatment is that the
CSCs are not affected by common therapeutic agents. CSCs have
the ability of infinite self-renewal and the capacity to differentiate
into the various populations of cells that comprise a tumor. Self-
renewal refers to the ability to create new stem cells with the
same potential for proliferation, development, and differentiation,
thereby maintaining the stem cell population. Induction of cancer
stem cells to differentiate may result in removal of their ability
of self-renewal. A niche is a special microenvironment where
stem cells are stored and characterized by having different factors
that can control stem cell proliferation and determination. In gen-
eral, the niche is kept in a state of stasis by creating a signal that
inhibits the growth and proliferation of stem cells. Stem cells can
only get activated in presence of the excitation signals which
make them start dividing and going into proliferation. So the bal-
ance between proliferation and inhibitory signals is the key for
stem cell homeostasis. Any disruption increases the risk of develop-
ing tumors.
Colorectal cancer stem cells and their markers: Several studies
identified a subpopulation of colorectal cancer cells that are more
resistant to cancer treatments (such as chemotherapy and radiation
therapy). Effective treatment depends on the elimination of these
resistant subpopulations. These cancer stem cells or tumor-initiating
cells have several highly expressed markers on their cell surface.
Important markers in colorectal cancer stem cells are CD24, CD29,
Lgr5, CD133 and CD44.
CD24 is a cell surface protein that is attached to the outer plasma
membrane. CD24+ subpopulations have cancer stem cell-like proper-
ties such as increased resistance to chemotherapy, self-renewal and
tumorigenic potential both in vitro and in vivo, compared to CD24-
cell subpopulations.
CD29 (B1- integrin) is a member of the integrin family and con-
tains a large extracellular and a short cytoplasmic domain that acts as
a receptor for extracellular matrix proteins. It also activates signaling
pathways to regulate cell migration, proliferation, permanence, differ-
entiation and death. CD29 also plays a role in colorectal cancer cell
metastasis.
LGR5 is a member of the Wnt signaling pathway. Although its
ligand is unclear, it is one of the stem cell markers in the intestinal
crypts. The findings show that LGR5 could play a key role in the
development of CRC and may be considered as a useful marker for
identifying and / or targeting colorectal cancer stem cells.
CD133 (or prominin-1) is a glycoprotein which is encoded by the
PROM1 gene in humans. While the accurate function of CD133 is
not clear yet, it appears to act as an organizer of the cell membrane
topology. However, the findings indicate that CD133 plays a key role
in the initiation and progression of colorectal cancer and can be usedas a marker of prognosis and diagnosis of CRC. CD44 is a cell adhe-
sion molecule that plays an important role in facilitating cell-cell
and cell-matrix interactions by connecting to its ligand such as hya-
luronic acid. CD44 also facilitates the assembly of growth factors on
the cell surface. Research has shown that CD44 could have a more
decisive role in the tumorigenesis of colorectal cancer cells. Further-
more, active participation in many cellular activities, such as sur-
vival, differentiation, and migration are some other properties of
CD44.
An effective treatment should be able to target all the different
microenvironments of colon cancer stem cells in tumors to inhibit pri-
mary tumor growth, metastasis and recurrence of cancer. A promising
method for increasing the efficiency of the treatment, is the use of
nanoparticles in the diagnosis and treatment process. Biocompatible
nanoparticles are conjugated with specific monoclonal antibodies
against CCSC markers and also are capable of carrying drugs or small
selectively directed RNAs to silence fundamental molecules for
CCSC survival.
There are monoclonal antibodies such as specific anti-human
CD133 mAb, anti human CD29 monoclonal antibody-clone 12G10,
SWA11 mAb and KM4056 mAb for CD133, CD29, CD24 and
Lgr5 antigens respectively. For a more effective and specific drug
delivery, it is suggested to target colorectal cancer stem cells with
specific antibody conjugated with nanoparticles which contain loaded
drug.
Inhibition of the expression of P53, HIF-1a and COX-2 genes as
well as inhibition of NF-kb, Wnt / b-catenin and K-Ras signaling and
also activation of TGF-b are strategies for the treatment of colorectal
cancer. Pending strategies for eradication of colorectal cancer stem
cells are as follows:
1) PI3K signaling impairment causes Inhibition of proliferation
and apoptosis induction
2) Hedgehog signaling impairment causes proliferation impair-
ment and apoptosis induction
3) Notch signaling impairment causes a decrease in tumor growth
and reduction in CCSCs frequency
4) Inhibition of IL-4 signaling causes sensitization to
chemotherapy
5) CD44 silencing causes apoptosis induction and tumor growth
suppression [19].
Nanotechnology and regulation of gene expression: Nano-
Script is an artificial nanoparticle with similar functional Transcrip-
tion Factor (TF) protein that in fact is a platform for regulating
gene expression. TF is a binding protein to specific sequence of
DNA, so regulates the rate of transcription of genetic information
from DNA to messenger RNA. NanoScript has two interesting fea-
tures that make it appropriate platform in the field of stem cells:
First, it is non-viral, that is a good alternative to viral vectors. Sec-
ond, simple arrangement of the sequence of any molecule on Nano-
Script is possible so they can specifically target and induce
differentiation.
Conclusion: In this review, we discussed the important role of
cancer stem cells in cancer recurrence, Then examined the role of
genes and signaling pathways in the progression of colorectal cancer
and it was shown that with the use of nanotechnology can be affected
the expression of genes and signaling pathways in cancer therapy to
specifically target cancer stem cells and lead to increased efficiency
of treatment.
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